Menu
Search Close

Investors

Share Information

Other exchanges or trading platforms where Scancell Holdings plc securities are admitted or traded:

Scancell Holdings securities are listed on AIM, and the latest share price is shown here

The number of securities in issue:

The company has an issued share capital of 387,796,556 ordinary shares of 0.1p each, all of which are called up and fully paid.

Pursuant to the License and Supply Agreement (‘the Agreement’) dated 13 July 2009, the Company has granted options over 3,184,630 ordinary shares to ICHOR at 4.5p per share.

Directors’ Share Options:

The Company has granted the following options to Directors of the Company. 

Option holder

Option price per ordinary share

Number of ordinary shares under option

Last day of exercise period

Sally Adams

10.5p

2,500,000

30 January 2028

John Chiplin

17.0p

3,000,000

18 April 2026

 Lindy Durrant

4.5p

3,850,000

14 July 2020

Lindy Durrant

10.5p

9,000,000

30 January 2028

Richard  Goodfellow

4.5p

2,880,000

14 July 2020

Richard  Goodfellow

33.2p

3,500,000

31 December 2023

Clifford Holloway

10.5p

3,000,000

30 January 2028

 

In addition to the above, the Company has granted options over 4,645,536 shares of the Company to various other persons at exercise prices between 2.5p and 33.2p.

Percentage of AIM securities not in public hands:

As at 31 January 2019 the percentage of AIM securities not in public hands was: 17.79%

Restrictions on the transfer of securities:

There are no restrictions on the transfer of shares.

Identity and percentage holdings of significant shareholders:

As at 6 March 2019 the identity and percentage holdings of significant shareholders were: 

 

Ordinary shares at 0.1p each

 

 Number

 Percentage

Calculus Capital

49,844,165

12.85%

Scancell Holdings plc directors and related holdings

19,163,147

4.94%

Legal & General Investment Management

16,300,000

4.20%

City Financial Investment Company

16,287,775

4.20%

Hygea VCT plc

13,249,730

3.42%

Webcasts, Interviews and Media Coverage

Scancell in vanguard of immuno-oncology advances, with two technologies that show early promise

The AIM-listed group is at the vanguard of advances in the emerging field of immuno-oncology and is working on two technologies that are showing early promise

Tue, 12 Feb 2019 15:07:00

Scancell lauds another six months of progress

The funds raised in the last year "will allow us to focus on initiating the planned Phase 2 clinical trial for our lead ImmunoBody, SCIB1, and to advance our Moditope products, Modi-1 and Modi-2, towards the clinic".

Thu, 31 Jan 2019 08:41:00

Award shortlist 'a significant scientific endorsement' of Scancell's technology

Cliff Holloway, chief executive of Scancell Holdings Plc (LON:SCLP), tells Proactive London's Andrew Scott the company's received “significant scientific endorsement” of its technology after it and a group of collaborators were shortlisted for a major award.

It teamed up with BioNTech, Genentech and ISA Pharmaceuticals to form Project Blueprint for Cancer Research UK’s Grand Challenge.

The team outlined plans to eradicate established tumours with its unique vaccine, which had Scancell’s Modi-3 treatment at its heart.

Wed, 23 Jan 2019 12:25:00